187 related articles for article (PubMed ID: 34224364)
1. VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.
Ekstrom TL; Pathoulas NM; Huehls AM; Kanakkanthara A; Karnitz LM
Mol Cancer Ther; 2021 Sep; 20(9):1561-1571. PubMed ID: 34224364
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
3. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
[TBL] [Abstract][Full Text] [Related]
6. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Wilkerson PM; Dedes KJ; Samartzis EP; Dedes I; Lambros MB; Natrajan R; Gauthier A; Piscuoglio S; Töpfer C; Vukovic V; Daley F; Weigelt B; Reis-Filho JS
Oncotarget; 2017 Jan; 8(4):6057-6066. PubMed ID: 28002809
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Chen L; Hou J; Zeng X; Guo Q; Deng M; Kloeber JA; Tu X; Zhao F; Wu Z; Huang J; Luo K; Kim W; Lou Z
Clin Transl Med; 2021 Mar; 11(3):e341. PubMed ID: 33784003
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
10. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
12. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou Q; Tu X; Hou X; Yu J; Zhao F; Huang J; Kloeber J; Olson A; Gao M; Luo K; Zhu S; Wu Z; Zhang Y; Sun C; Zeng X; Schoolmeester KJ; Weroha JS; Hu X; Jiang Y; Wang L; Mutter RW; Lou Z
Drug Resist Updat; 2024 May; 74():101085. PubMed ID: 38636338
[TBL] [Abstract][Full Text] [Related]
13. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
[TBL] [Abstract][Full Text] [Related]
14. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
16. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
17. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
Onji H; Murai J
Cancer Sci; 2022 Sep; 113(9):2943-2951. PubMed ID: 35766436
[TBL] [Abstract][Full Text] [Related]
18. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
19. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
